ALNY - ALNYLAM PHARMACEUTICALS, INC.

QQQ $ 621.60 $ 0.98 (0.16 %)

DIA $ 478.76 $ 4.65 (0.98 %)

SPY $ 682.72 $ 2.76 (0.41 %)

TLT $ 89.90 $ -0.04 (-0.04 %)

GLD $ 377.99 $ -2.02 (-0.53 %)

Previous Close

$ 441.7

Open

$ 445.17

Bid

$ 451.79 x 5

Ask

$ 452.45 x 2

Day's Range

$ 442.15 - $ 453.82

52 Week Range

$ 205.87 - $ 495.55

Volume

739,044

Average Volume

Market Cap

58.35B

Beta (5Y Monthly)

$ 0.96

PE Ratio (TTM)

$ 1,339.49

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	10-30-2025	09-30-2025	10-Q
2	07-31-2025	06-30-2025	10-Q
3	05-01-2025	03-31-2025	10-Q
4	02-13-2025	12-31-2024	10-K
5	10-31-2024	09-30-2024	10-Q
6	08-01-2024	06-30-2024	10-Q
7	05-02-2024	03-31-2024	10-Q
8	02-15-2024	12-31-2023	10-K
9	11-02-2023	09-30-2023	10-Q
10	08-03-2023	06-30-2023	10-Q
11	05-04-2023	03-31-2023	10-Q
12	02-23-2023	12-31-2022	10-K
13	10-27-2022	09-30-2022	10-Q
14	07-28-2022	06-30-2022	10-Q
15	04-28-2022	03-31-2022	10-Q
16	02-10-2022	12-31-2021	10-K
17	10-28-2021	09-30-2021	10-Q
18	08-03-2021	06-30-2021	10-Q
19	04-29-2021	03-31-2021	10-Q
20	02-11-2021	12-31-2020	10-K
21	11-05-2020	09-30-2020	10-Q
22	08-06-2020	06-30-2020	10-Q
23	05-06-2020	03-31-2020	10-Q
24	02-13-2020	12-31-2019	10-K
25	10-31-2019	09-30-2019	10-Q
26	08-06-2019	06-30-2019	10-Q
27	05-02-2019	03-31-2019	10-Q
28	02-14-2019	12-31-2018	10-K
29	11-07-2018	09-30-2018	10-Q
30	08-02-2018	06-30-2018	10-Q
31	05-04-2018	03-31-2018	10-Q
32	02-15-2018	12-31-2017	10-K
33	11-07-2017	09-30-2017	10-Q
34	08-09-2017	06-30-2017	10-Q
35	05-05-2017	03-31-2017	10-Q
36	02-15-2017	12-31-2016	10-K
37	11-03-2016	09-30-2016	10-Q
38	08-04-2016	06-30-2016	10-Q
39	05-04-2016	03-31-2016	10-Q
40	02-12-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wells Fargo Maintains Equal-Weight on Alny...
11/11/2025 14:25:09

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price t...

Reported Saturday, Alnylam Pharmaceuticals...
11/10/2025 08:58:47

− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran's Differentiated Prof...

Here's How Much $1000 Invested In Alnylam ...
11/07/2025 22:15:39

What Does the Market Think About Alnylam P...
11/06/2025 19:02:13

Royalty Pharma Acquires Royalty Interest I...
11/04/2025 12:18:09

Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds m...

Piper Sandler Reiterates Overweight on Aln...
10/31/2025 15:35:51

Piper Sandler analyst Edward Tenthoff reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the pric...

Barclays Maintains Overweight on Alnylam P...
10/31/2025 15:14:04

Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target fro...

why-is-alnylam-pharmaceuticals-stock-trading-lower-thursday

Why Is Alnylam Pharmaceuticals Stock Tradi...
10/30/2025 18:39:12

Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales gui...

meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday

Meta Tumbles 10%, Google Marks Historic Ra...
10/30/2025 17:40:46

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

Alnylam Pharmaceuticals Raises FY2025 Sale...
10/30/2025 12:25:54

Alnylam Pharmaceuticals (NASDAQ:ALNY) raises FY2025 sales outlook from $3.300 billion-$3.550 billion to $3.600 billion-$3.800 b...

Alnylam Says Received Subpoena From US Att...
10/30/2025 12:16:56

Alnylam Expects To Initiate Phase 2 Trial ...
10/30/2025 12:02:31

Alnylam Pharmaceuticals Q3 Adj. EPS $2.90 ...
10/30/2025 12:01:23

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $2.90 per share which beat the analyst consensus estimate ...

Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

Uncovering Potential: Alnylam Pharmaceutic...
10/29/2025 14:04:05

intellia-freezes-key-trial-after-serious-liver-event-stock-tumbles

Intellia Freezes Key Trial After Serious L...
10/27/2025 14:38:29

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related advers...

Peering Into Alnylam Pharmaceuticals Inc's...
10/21/2025 14:00:42

Truist Securities Maintains Buy on Alnylam...
10/17/2025 13:46:03

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price tar...

$1000 Invested In Alnylam Pharmaceuticals ...
10/14/2025 16:30:44

JP Morgan Maintains Overweight on Alnylam ...
10/13/2025 13:53:37

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target ...